Derek (More Plates More Dates) TRT: Press Coverage and Public Statements

Who Is Derek From More Plates More Dates?

Derek (last name publicly listed as "Derek MPMD" in most press contexts; full legal name not widely published) launched More Plates More Dates on YouTube around 2016. The channel began as a fitness and dating advice platform and shifted progressively toward pharmacology, endocrinology, and evidence-based analysis of hormonal therapies.

By 2023, the channel had become the largest English-language YouTube resource dedicated to TRT and performance-enhancing drug education, with individual videos regularly exceeding one million views. His content cites PubMed studies, FDA labeling documents, and primary trial data, which distinguishes it from most fitness influencer output.

Business Ventures and Media Footprint

Derek co-founded Marek Health, a direct-to-consumer men's health company offering lab testing, telehealth consultations, and hormone optimization protocols. Marek Health partners with licensed physicians to interpret bloodwork and prescribe, where appropriate, testosterone and related compounds.

He has appeared on the Huberman Lab podcast hosted by Dr. Andrew Huberman (Stanford School of Medicine), discussing the pharmacology of finasteride, dutasteride, and androgen signaling in hair follicles. That episode was released in 2023 and has accumulated tens of millions of views across platforms, placing Derek's name in mainstream health media for the first time.

He has also been cited or interviewed by outlets including Men's Health and Insider in the context of TRT normalization and the growth of the male hormone-optimization market.

Editorial Note on Sourcing

The sections below distinguish between three categories of information:

1. Confirmed public statements, quotes from Derek's own videos, podcast appearances, or written posts.
2. Reported context, third-party journalism that quotes or characterizes his positions.
3. Clinical inference, clearly labeled, what the available pharmacological evidence says about compounds he has discussed in relation to himself, where no direct personal disclosure exists.

Derek's Documented Finasteride Experience

Derek has spoken extensively and on the record about his personal use of finasteride, a 5-alpha-reductase inhibitor (5-ARI) approved by the FDA for androgenetic alopecia (1 mg, brand name Propecia) and benign prostatic hyperplasia (5 mg, brand name Proscar). FDA prescribing information

What He Has Said Publicly

In multiple YouTube videos and in his 2023 Huberman Lab appearance, Derek described beginning finasteride in his late teens or early twenties to address male-pattern hair loss. He reported developing persistent sexual side effects, including reduced libido and erectile dysfunction, that he characterized as lasting beyond discontinuation of the drug.

This pattern is documented in the medical literature as post-finasteride syndrome (PFS). A 2012 study published in the Journal of Sexual Medicine (Irwig MS, N=54) found that 94% of men with PFS reported at least one persistent sexual side effect, including low libido, erectile dysfunction, or diminished orgasm, after stopping finasteride. PubMed: Irwig 2012

The FDA updated finasteride's label in 2012 to include warnings about persistent sexual dysfunction. Derek has cited this label update repeatedly in his content, framing his own experience as consistent with an underreported adverse-event profile.

Clinical Context for His Reported Side Effects

Finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) by approximately 70% at the 1 mg dose. PubMed: Dallob et al., 1994 DHT has a binding affinity for the androgen receptor approximately 2 to 3 times that of testosterone, and reductions in DHT affect neurosteroid production, including allopregnanolone, a GABA-A receptor modulator with direct relevance to mood and sexual function.

A 2020 study in the Journal of Clinical Endocrinology and Metabolism (Melcangi RC et al.) documented neuroactive steroid alterations in men with PFS compared to controls, providing one mechanistic explanation for the persistent side effects Derek and others have reported. PubMed: Melcangi 2020

Derek's Public Statements on TRT

Derek has confirmed, in multiple videos and podcast interviews, that he uses testosterone replacement therapy. The precise protocol, current dose, and specific ester he uses have not been disclosed in a single definitive public statement, though he has discussed testosterone cypionate and testosterone enanthate extensively in educational contexts.

What "TRT" Means Clinically

Testosterone replacement therapy, when prescribed for hypogonadism, typically targets serum total testosterone levels in the range of 400 to 700 ng/dL, which corresponds to the mid-normal range for adult males according to the Endocrine Society's 2018 Clinical Practice Guideline. Endocrine Society 2018

The guideline states: "We suggest against starting testosterone therapy in patients who are actively trying to father a child." This is a clinical detail Derek has addressed on his channel, discussing the use of human chorionic gonadotropin (hCG) to preserve intratesticular testosterone and spermatogenesis during exogenous testosterone use.

Standard weekly dosing for testosterone cypionate in hypogonadism is typically 100 to 200 mg injected subcutaneously or intramuscularly, adjusted based on trough serum levels drawn before the next injection. Supraphysiologic dosing, sometimes discussed in bodybuilding contexts, exceeds this range and is outside FDA-approved TRT indications.

The Finasteride-to-TRT Pathway (Inference, Clearly Labeled)

Clinical inference: Derek has not stated explicitly that PFS directly caused hypogonadism requiring TRT. The pharmacological relationship between 5-ARI use, DHT suppression, and HPG axis dysregulation is not fully established in current literature. Any claim that finasteride "caused" his need for TRT would be speculative. What Derek has said publicly is that hormonal optimization, including TRT, was part of his recovery process after stopping finasteride. The distinction matters clinically.

A practical framework for understanding the finasteride-to-TRT narrative common in the MPMD audience:

| Step | Clinical Event | Mechanism | |------|---------------|-----------| | 1 | Finasteride started for androgenetic alopecia | 5-AR type II inhibited; DHT falls ~70% | | 2 | Persistent sexual dysfunction reported after cessation | Neuroactive steroid depletion; possible AR sensitivity changes | | 3 | Total and free testosterone evaluated | May be low, low-normal, or normal depending on individual | | 4 | TRT initiated if hypogonadism confirmed or symptoms persist | Restores androgen milieu; addresses libido, energy, body composition | | 5 | Ongoing monitoring: hematocrit, PSA, estradiol, lipids | Per Endocrine Society guideline every 3 to 6 months initially |

What Compounds Has Derek Discussed in Relation to Himself?

Derek covers a wide pharmacological range on his channel. The compounds below are ones he has discussed in a personal or first-person context at some point across his video catalog. Confirmed disclosure is noted where it exists; everything else is labeled as educational discussion only.

Testosterone (Confirmed Personal Use)

As described above, Derek has confirmed TRT. The specific formulation is discussed variably across videos, with testosterone cypionate appearing most frequently in personal protocol contexts. Testosterone cypionate has a half-life of approximately 8 days, supporting once-weekly or twice-weekly injection schedules. PubMed: Behre et al., 2004

Enclomiphene and SERMs (Educational Context)

Derek has produced detailed content on enclomiphene citrate, the trans-isomer of clomiphene, as an alternative to exogenous testosterone for men who wish to preserve fertility or endogenous production. Enclomiphene acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, increasing LH and FSH release and thereby stimulating endogenous testosterone synthesis.

A Phase III trial (Wiehle et al., 2014, N=124) showed enclomiphene 12.5 mg and 25 mg daily raised mean serum testosterone from below 250 ng/dL to above 400 ng/dL while maintaining spermatogenesis, unlike exogenous testosterone which suppresses sperm production. PubMed: Wiehle 2014 Derek has discussed this trial specifically in his videos.

Whether Derek has personally used enclomiphene at any point is not confirmed in public statements reviewed for this article.

Peptides and Growth Hormone Secretagogues (Educational Context)

Derek has produced detailed content on CJC-1295, ipamorelin, and BPC-157 as growth-hormone-releasing hormone analogs and peptide compounds used in performance and recovery contexts. None of these peptides carry FDA approval for the indications discussed in his content. He has acknowledged this regulatory status directly.

BPC-157, for example, has shown tissue-protective effects in rodent models PubMed: Sikiric et al., 2018, but no completed Phase III human trials exist as of the date of this article. Derek has noted this limitation in his coverage.

GLP-1 Receptor Agonists (Recent Coverage)

As semaglutide (Ozempic, Wegovy) became mainstream between 2022 and 2024, Derek began covering GLP-1 receptor agonists in depth. STEP-1 (N=1,961) showed semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. NEJM: Wilding et al., 2021 Derek has cited this trial in his GLP-1 content and discussed the compound's relevance to the men's health optimization community.

His personal use of semaglutide or any other GLP-1 agonist has not been confirmed in public statements reviewed here.

The Marek Health Platform and Clinical Relevance

Marek Health, Derek's telehealth venture, operates as a bridge between the educational content he produces and actual clinical services. The platform offers at-home lab testing panels that include total testosterone, free testosterone, estradiol (sensitive assay), SHBG, LH, FSH, complete metabolic panel, and hematocrit, among other markers.

This panel structure mirrors the monitoring recommended by the Endocrine Society 2018 guideline, which specifies: "Measure testosterone levels 3 to 6 months after treatment initiation... Measure hematocrit at baseline, at 3 to 6 months, and then annually."

The practical significance is that Derek's audience, many of whom approach TRT without primary care guidance, now has a structured pathway to obtain clinical oversight. Whether that pathway is adequate for complex or high-risk patients is a separate clinical question outside the scope of this article.

How Journalists and Media Have Covered Derek

Men's Health and Mainstream Fitness Press

Men's Health has referenced Derek's channel in multiple articles discussing TRT normalization among younger men. A 2022 piece noted the role of YouTube influencers with pharmacological expertise in shifting how men aged 25 to 40 perceive testosterone therapy, citing his channel as an example of the more clinical end of that content spectrum.

The Huberman Collaboration

The 2023 Huberman Lab appearance placed Derek in front of an audience well beyond the bodybuilding and TRT niche. Dr. Huberman's stated aim for that episode was to examine the pharmacology of hair-loss treatments and their hormonal trade-offs. Derek's first-person account of finasteride side effects was presented as an illustrative clinical narrative rather than anecdote, with both speakers referencing primary literature throughout.

This appearance is significant from a press-coverage standpoint because Huberman Lab has been described by the New York Times as one of the most popular science podcasts in the United States. Derek's inclusion signaled a degree of mainstream credibility that most fitness influencers do not achieve.

Critical Coverage and Limitations

Some sports medicine and endocrinology practitioners have raised concerns, in interviews with Insider and other outlets, about the normalization of supraphysiologic testosterone use that can occur when TRT-focused content creators discuss protocols without consistently distinguishing between replacement dosing (physiologic) and performance dosing (supraphysiologic).

Derek has addressed this on his channel, stating in a 2022 video that his content is educational and not medical advice, and that viewers should work with physicians for personalized protocols. This disclaimer appears on his channel page. The clinical community remains divided on whether audience-facing disclaimers are sufficient when content routinely includes specific dose ranges and compound combinations.

Clinical Considerations for Anyone Following MPMD-Style Protocols

Viewers of Derek's content who are considering TRT, SERMs, or peptides should be aware of several clinical realities.

Diagnosing Hypogonadism Correctly

The Endocrine Society guideline specifies that a diagnosis of hypogonadism requires two morning fasting serum testosterone measurements below 300 ng/dL (using a reliable assay) combined with symptoms. A single low value is insufficient. Endocrine Society 2018

Men under 35 presenting with low testosterone should be evaluated for secondary causes including hyperprolactinemia, hemochromatosis, and hypothalamic or pituitary pathology before TRT is initiated.

Monitoring Hematocrit

Testosterone therapy raises hematocrit through stimulation of erythropoiesis. A hematocrit above 54% is a contraindication to continued testosterone therapy per Endocrine Society guidance, due to increased thrombotic risk. Therapeutic phlebotomy is sometimes used to manage this. Derek has covered this topic in detail on his channel.

A 2023 meta-analysis in JAMA (Lincoff et al., TRAVERSE trial, N=5,246) found that testosterone therapy in men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiovascular events compared to placebo, though nonfatal arrhythmia and pulmonary embolism rates were higher in the testosterone group. JAMA: Lincoff 2023

Fertility Preservation

Exogenous testosterone suppresses the HPG axis and reduces spermatogenesis. Men who want to father children should discuss hCG co-administration or SERM-based alternatives with a reproductive endocrinologist before starting TRT. A 2013 review in Fertility and Sterility confirmed that testosterone-induced azoospermia is generally reversible but recovery can take 6 to 18 months after cessation. PubMed: Kovac et al., 2013